Poor
Not Aligned
Patient Risk:
Moderate
Summary
Many specific efficacy/safety and counseling claims (e.g., 'most common' adverse effects with exact percentages, allergy manifestations, seizure worsening, hydration, driving restrictions) are not supported by the provided FDA label excerpts. Several statements are broader than what is present or cannot be confirmed due to missing label text (e.g., indication, pregnancy/lactation safety).
Category Scores
Accurate Statements
Patients should start with a low dose and gradually increase as needed and tolerated.
2.1 Dosage Information: dosage should be increased based on clinical response and tolerability; titration not more frequently than once per week. (Low-dose phrasing not explicitly supported.)
Suicidal thoughts and behaviors have been reported in patients taking lacosamide.
5.1 Suicidal Behavior and Ideation: AEDs, including MOTPOLY XR, increase the risk of suicidal thoughts or behavior.
Patients with kidney disease may need to adjust their dosage of lacosamide or avoid taking it altogether.
2.3 Dosage Information for Patients with Renal Impairment: no adjustment needed for mild to moderate renal impairment; maximum recommended dosage is 300 mg for severe renal impairment or end-stage renal disease; titration based on response/tolerability. (Avoid altogether not supported.)
Patients with liver disease may need to adjust their dosage of lacosamide or avoid taking it altogether.
2.4 Dosage Information for Patients with Hepatic Impairment: max recommended dosage is 300 mg for mild/moderate hepatic impairment; not recommended in severe hepatic impairment. (Avoid altogether broadly not supported.)
Lacosamide works by stabilizing abnormal electrical activity in the brain, reducing the frequency and severity of seizures.
12.1 Mechanism of Action: stabilizes hyperexcitable neuronal membranes and inhibits repetitive neuronal firing. (Explicit 'reducing frequency and severity of seizures' not present in provided excerpt.)
Unsupported Statements
The most common side effects of lacosamide include dizziness (14% of patients).
No frequency percentages or 'most common' adverse reaction data are provided in the supplied label excerpts.
The most common side effects of lacosamide include headache (12% of patients).
No supplied label excerpt provides headache frequency/% data.
The most common side effects of lacosamide include fatigue (10% of patients).
No supplied label excerpt provides fatigue frequency/% data.
The most common side effects of lacosamide include nausea (8% of patients).
No supplied label excerpt provides nausea frequency/% data.
The most common side effects of lacosamide include drowsiness (6% of patients).
No supplied label excerpt provides drowsiness frequency/% data.
Allergic reactions to lacosamide can occur rarely.
While DRESS/multiorgan hypersensitivity reactions are listed as serious adverse reactions, the provided excerpts do not support 'allergic reactions' as framed nor a 'rarely' frequency.
Allergic reactions to lacosamide may manifest as hives, itching, or difficulty breathing.
No supplied label excerpt describes these specific manifestations for hypersensitivity/allergic reactions.
In rare cases, lacosamide may increase the frequency or severity of seizures.
No supplied label excerpt supports seizure worsening/increased frequency or 'rare cases' language.
The increased seizure frequency or severity with lacosamide is especially noted in patients with a history of complex partial seizures.
No supplied label excerpt supports seizure worsening, and no subgroup such as 'complex partial seizures' is mentioned.
Suicidal thoughts and behaviors with lacosamide are especially reported in the first few months of treatment.
Label excerpt supports risk observed as early as one week and persisting during assessed treatment, but does not support 'especially in the first few months' wording.
Some patients may experience weight gain with lacosamide.
No supplied label excerpt provides weight gain information.
Depression has been reported in patients taking lacosamide.
5.1 excerpt discusses monitoring for emergence or worsening of depression but does not state 'depression has been reported' as a claim.
Patients should monitor for side effects and report concerns to their doctor.
17 Patient Counseling excerpt provided only advises reading the Medication Guide; no specific monitoring/reporting instruction is shown.
Patients should stay hydrated (drink plenty of water) to help reduce the risk of dizziness and nausea with lacosamide.
No supplied label excerpt links hydration to reducing dizziness/nausea or provides hydration counseling.
Patients should avoid driving or operating heavy machinery until they know how lacosamide affects them.
No supplied label excerpt includes driving/machinery restriction guidance.
The safety of lacosamide during pregnancy is not well-established.
Although pregnancy and lactation headers exist, no pregnancy safety text is provided in the supplied excerpts, so the claim cannot be confirmed.
The safety of lacosamide during breastfeeding is not well-established.
Although pregnancy and lactation headers exist, no lactation safety text is provided in the supplied excerpts, so the claim cannot be confirmed.
Lacosamide is a medication used to treat epilepsy.
The supplied excerpts do not include the 'INDICATIONS AND USAGE' text needed to confirm approved use for epilepsy.
Patients with heart problems, such as atrial fibrillation, may need to avoid taking lacosamide due to the risk of increased heart rate.
The provided excerpts mention 'Cardiac Rhythm and Conduction Abnormalities' but do not specify atrial fibrillation, increased heart rate, or avoidance instructions.
Contradictions
Important Omissions
Approved indication(s) for MOTPOLY XR (e.g., specific seizure types/monotherapy/adjunctive therapy) from the 'INDICATIONS AND USAGE' section.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims introduce specific quantitative adverse effect frequencies, allergy manifestations, seizure-worsening language, and counseling (hydration, driving) that are not supported by the provided label excerpts. Missing/unsupported safety counseling and subgroup/rare-event framing could misinform patients or clinicians if treated as label-accurate.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Large portion of extracted claims are not supported by the supplied FDA label excerpts, including exact 'most common' adverse effect percentages, allergy manifestations, seizure-worsening assertions, and specific patient counseling (hydration/driving). Several safety/population claims (pregnancy/lactation, indication) cannot be confirmed due to missing label text.
Suggested Improvement
Restrict statements to what is explicitly present in the provided label excerpts (e.g., titration frequency and response/tolerability basis; renal/hepatic dosing limitations; suicidal ideation risk language; hypersensitivity categories). Remove unsupported quantitative AE percentages and specific counseling not present in the excerpted label sections. Provide or request the missing 'INDICATIONS AND USAGE', '8.1 Pregnancy', '8.2 Lactation', and relevant AE frequency sections to enable accurate evaluation.